RSLV-132

RSLV-132, our lead product candidate, is a novel compound that eliminates inflammatory nucleic acids, which are known to accumulate in lupus and Sjögren’s syndrome patients and cause chronic inflammation.

RSLV-145

This compound is a prototype of a platform of nuclease Fc fusion proteins Resolve scientists have created that have both RNase catalytic activity and DNase catalytic activity. We have engineered the nucleases in multiple different formats that give rise to numerous therapeutic applications. These are potent antagonists of the inflammatory properties of both RNA and DNA with potential therapeutic utility in lupus, lupus nephritis, vasculitis and autoimmune diseases that involve NETosis. The death of neutrophils often creates a dense lattice of DNA and RNA which forms a scaffold for autoantigens that bind to autoantibodies present in the blood of patients with autoimmune disease. By digesting neutrophil NETS, RSLV-145 eliminates the scaffold holding these autoantigens together and prevents the concentrated activation of the immune system at that point. In the case of vasculitis, the NETS are present on the vascular endothelium and causes severe vascular inflammation characteristic of this disease. Similar pathogenic nucleic acids have been observed in lupus and lupus nephritis.